Oncotarget

Research Papers:

Limited fibrosis accompanies triple-negative breast cancer metastasis in multiple model systems and is not a preventive target

Danielle Brooks, Alexandra Zimmer, Lalage Wakefield, L. Tiffany Lyle, Simone Difilippantonio, Fabio C. Tucci, Stephane Illiano, Christina M. Annunziata and Patricia S. Steeg _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:23462-23481. https://doi.org/10.18632/oncotarget.25231

Metrics: PDF 714 views  |   HTML 1143 views  |   ?  


Abstract

Danielle Brooks1, Alexandra Zimmer1, Lalage Wakefield2, L. Tiffany Lyle3, Simone Difilippantonio4, Fabio C. Tucci5, Stephane Illiano6, Christina M. Annunziata1 and Patricia S. Steeg1

1Women’s Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA

2Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA

3Department of Comparative Pathobiology, Purdue University College of Veterinary Medicine, West Lafayette, IN, USA

4Laboratory Animal Sciences Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA

5Epigen Biosciences, Inc., San Diego, CA, USA

6Sanofi, Chilly Mazarin, France

Correspondence to:

Patricia S. Steeg, email: steegp@mail.nih.gov

Keywords: breast cancer; ovarian cancer; fibrosis; lysophosphatidic acid receptor; metastasis

Received: December 29, 2017     Accepted: April 04, 2018     Published: May 04, 2018

ABSTRACT

The lysophosphatidic acid receptor 1 (LPAR1) is mechanistically implicated in both tumor metastasis and tissue fibrosis. Previously, metastasis was increased when fulminant fibrosis was first induced in mice, suggesting a direct connection between these processes. The current report examined the extent of metastasis-induced fibrosis in breast cancer model systems, and tested the metastasis preventive efficacy and fibrosis attenuation of antagonists for LPAR1 and Idiopathic Pulmonary Fibrosis (IPF) in breast and ovarian cancer models. Staining analysis demonstrated only focal, low-moderate levels of fibrosis in lungs from eleven metastasis model systems. Two orally available LPAR1 antagonists, SAR100842 and EPGN9878, significantly inhibited breast cancer motility to LPA in vitro. Both compounds were negative for metastasis prevention and failed to reduce fibrosis in the experimental MDA-MB-231T and spontaneous murine 4T1 in vivo breast cancer metastasis models. SAR100842 demonstrated only occasional reductions in invasive metastases in the SKOV3 and OVCAR5 ovarian cancer experimental metastasis models. Two approved drugs for IPF, nintedanib and pirfenidone, were investigated. Both were ineffective at preventing MDA-MB-231T metastasis, with no attenuation of fibrosis. In summary, metastasis-induced fibrosis is only a minor component of metastasis in untreated progressive breast cancer. LPAR1 antagonists, despite in vitro evidence of specificity and efficacy, were ineffective in vivo as oral agents, as were approved IPF drugs. The data argue against LPAR1 and fibrosis as monotherapy targets for metastasis prevention in triple-negative breast cancer and ovarian cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 25231